RaySearch Laboratories AB (LTS:0GRZ)
kr 232.2 +7.2 (+3.2%) Market Cap: 7.91 Bil Enterprise Value: 7.84 Bil PE Ratio: 35.83 PB Ratio: 7.70 GF Score: 83/100

Q4 2025 RaySearch Laboratories AB (publ) Earnings Call Transcript

Feb 12, 2026 / 10:00 AM GMT
Release Date Price: kr169.2 (-4.30%)

Key Points

Positve
  • RaySearch Laboratories AB (RSLBF) achieved record high net sales in Q4 2025, growing by 16% to 375 million Swedish crowns.
  • The company reported a 25% increase in operating profit for Q4, reaching 92 million Swedish crowns, with a margin of 24%.
  • For the full year 2025, net sales increased by 13% to 1.34 billion Swedish crowns, marking the highest annual revenue in the company's history.
  • RaySearch Laboratories AB (RSLBF) continues to see strong momentum with license sales to both new and existing customers across all regions.
  • The company has made significant clinical progress, including the world's first clinical proton arc treatments, which was recognized as one of the top 10 scientific breakthroughs of the year by Physics World.
Negative
  • Currency headwinds negatively impacted the company's financial results, with adjusted growth figures showing a higher potential growth rate.
  • The order backlog has decreased, partly due to currency effects, which could be a concern for future revenue growth.
  • There are challenges in the seamless implementation of online adaptive radiotherapy without the full integration of RayCare.
  • The Pinnacle conversion rate was lower than expected in Q4, indicating potential challenges in converting existing clinics.
  • Administrative costs remained high in Q4, raising questions about cost management despite the absence of extraordinary costs in that quarter.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

RAYb.ST - RaySearch Laboratories AB (publ)
Q4 2025 RaySearch Laboratories AB (publ) Earnings Call
Feb 12, 2026 / 10:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
A warm welcome to Research 2025 year and results presentation. My name is Carolina Stemblit, and I'm head of investor relations. With me today are our CEO and founder, Johan Lou and our CFO Nina Grombey, who will take you through the key highlights and financial results.

After the presentation, we will open up for questions. Feel free to submit them in the Q&A chat or ask them live. With that said, CNY, over to you.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Carolina, and welcome again, everyone.

So this is the agenda
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot